- RAPT Therapeutics (RAPT, Financial) appoints Dr. Jessica Savage as Vice President of Clinical Development.
- Plans to initiate Phase 2b clinical trials for RPT904 in food allergy by second half of 2025.
- RPT904 targets immunoglobin E (IgE) for treatment of allergic diseases.
RAPT Therapeutics, Inc. (RAPT), a clinical-stage biopharmaceutical company, has announced the appointment of Dr. Jessica Savage as Vice President of Clinical Development. Dr. Savage will lead the development of RPT904, a pioneering monoclonal antibody targeting immunoglobin E (IgE), which is a key factor in allergic diseases.
The company is gearing up to initiate a Phase 2b clinical trial for RPT904 aimed at treating food allergies in the second half of 2025. Additionally, there will be a focus on chronic spontaneous urticaria (CSU), expanding the drug's potential therapeutic applications.
Dr. Savage is a board-certified allergist and immunologist with extensive experience in food allergy research and clinical development. Her past roles include significant positions at prestigious institutions such as Harvard Medical School and Johns Hopkins University, as well as a leadership role at Alexion Pharmaceuticals. At Alexion, she led the clinical development strategies for various treatments, further showcasing her expertise in the field.
The appointment of Dr. Savage is a strategic move by RAPT Therapeutics to bolster its leadership team with her deep expertise and to advance the company's clinical development plans. This comes as part of RAPT's commitment to advancing innovative solutions for allergic diseases, addressing a significant unmet need in the medical community.
